Loading
Theravance Biopharma, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 09 Aug 2024.
Theravance Biopharma, Inc.: what insiders have been doing
This page follows insider dealings at Theravance Biopharma, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 58 filings signed by 14 insiders.
Only sales appear on the open market, 10 sales in all totalling €1.5M, filed by 3 insiders. Broshy Eran filed the largest sale, €472k, on 13 November 2025.
Across the 5,812 companies tracked on its exchange, the median is 19 filings; at 58 filings, this issuer sits above that mark. The full history, which starts in 2021, counts 2 purchases against 34 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 107.5 m USD and net income of 105.9 m USD.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
244
Thresholds
n/a
Buy Volume
€15M
2 ops. · all time
Sell Volume
€3M
34 ops. · all time
Who traded when
BuySaleRhonda Farnum10 sales
Eran Broshy3 sales
Eli Samaha2 sales
Since the insiders bought
- +68.2%Entry US$8.25 · Close at T+365 US$13.88
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Theravance Biopharma, Inc. Hold (neutral), based on 3 analysts. Average price target: US$17.67.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 157 of 24,148 companies
89.0
score / 100
Value88
Quality90
FCF yld27%
Earn yld12%
EV/EBITDA6.9x
ROE21%
Gross mgn·
Net mgn99%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$17.03
Analyst consensus
3 analystsHold
US$17.00Target US$17.67(+4%)US$19.00
Income statement
RevenueUS$107.5M
EBITDAUS$134.5M125% margin
Net incomeUS$105.9M51.6% margin
Valuation
PER (trailing)16.4x
PER (forward)13.4x
P/Book3.1x
Beta0.25
Balance sheet & cash
Market capUS$884.2M
Total debtUS$42.7M
Free Cash FlowUS$238.5M
Debt / Equity13%
Profitability & ownership
ROE20.9%
ROA1.3%
% insiders4.6%
% institutions94.7%
Last declaration on 28 September 2026
Declarations244 total
7,457,060 shares@ US$17.0014.24% mcap100.0% of flowOrdinary Share $0.00001 Par ValueSEC:0001357550-26-000033:0
89,062 sharesOrdinary SharesSEC:0001898490-26-000017:1
42,137 sharesOrdinary SharesSEC:0001833453-26-000009:0
107,812 sharesOrdinary SharesSEC:0001966698-26-000011:1
23,439 sharesOrdinary SharesSEC:0001966698-26-000011:2
223,917 sharesOrdinary SharesSEC:0001966698-26-000011:0
124,414 sharesOrdinary SharesSEC:0001898490-26-000017:0
6,009 sharesOrdinary SharesSEC:0001833453-26-000009:1
91,204 sharesOrdinary SharesSEC:0001199297-26-000006:0
6,009 sharesOrdinary SharesSEC:0001199297-26-000006:1
93,108 sharesOrdinary SharesSEC:0002012524-26-000011:0
96,718 sharesOrdinary SharesSEC:0002012524-26-000011:1
74,204 sharesOrdinary SharesSEC:0001625377-26-000007:0
6,009 sharesOrdinary SharesSEC:0001625377-26-000007:1
58,065 sharesOrdinary SharesSEC:0001270734-26-000007:0
6,009 sharesOrdinary SharesSEC:0001270734-26-000007:1
204,966 sharesOrdinary SharesSEC:0001961289-26-000011:0
108,436 sharesOrdinary SharesSEC:0001961289-26-000011:1
23,439 sharesOrdinary SharesSEC:0001961289-26-000011:2
74,980 sharesOrdinary SharesSEC:0001589602-26-000005:0
6,009 sharesOrdinary SharesSEC:0001589602-26-000005:1
1,382,272 sharesOrdinary SharesSEC:0001302443-26-000018:0
151,875 sharesOrdinary SharesSEC:0001302443-26-000018:1
76,875 sharesOrdinary SharesSEC:0001302443-26-000018:2
23,400 sharesOrdinary SharesSEC:0001302443-26-000018:3
25 of 244 declarations
About Theravance Biopharma, Inc.
Theravance Biopharma, Inc. is a U.S.-listed biopharmaceutical company trading on the NASDAQ under the ticker TBPH. Operationally, the company is split between South San Francisco, California, in the United States, and Dublin, Ireland. It became an independent publicly traded company on June 2, 2014, following its separation from Theravance, Inc. The company’s mission is to develop and commercialize differentiated medicines, with a particular emphasis on specialty respiratory disease. ([investor.theravance.com](https://investor.theravance.com/news-releases/news-release-details/theravance-inc-and-theravance-biopharma-inc-announce-completion?utm_source=openai))
Theravance Biopharma’s business model has gradually shifted from a broad research-and-development biotech toward a more focused company centered on a streamlined portfolio. Its commercial anchor is YUPELRI® (revefenacin) inhalation solution, an FDA-approved maintenance treatment for chronic obstructive pulmonary disease (COPD). The company highlights decades of respiratory-disease expertise and positions itself around “medicines that make a difference,” with value creation coming from both a marketed product and selective pipeline optionality. ([theravance.com](https://www.theravance.com/about-us/our-company/?utm_source=openai))
Read moreShow less
In competitive terms, TBPH is best viewed as a specialized small/mid-cap biotech rather than a diversified pharma platform. That specialization allows management to concentrate capital and operating attention on a narrow set of therapeutic opportunities where it believes it can build durable value. The company also relies on collaboration structures and shared commercialization economics, particularly for YUPELRI in the U.S. with Viatris, which reduces the burden of building a fully integrated sales organization from scratch. ([investor.theravance.com](https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-inc-reports-third-quarter-2025-financial?utm_source=openai))
Recent developments have been especially important for the investment case. In March 2026, Theravance Biopharma reported fourth-quarter and full-year 2025 results, citing another record quarter of non-GAAP profitability, record brand-level profitability for YUPELRI, and a strengthened balance sheet. At the same time, the company’s ampreloxetine program became the key clinical catalyst: enrollment in the pivotal CYPRESS Phase 3 study was completed in 2025, but topline results announced in March 2026 showed the study did not meet its primary endpoint. Following that outcome, the board accelerated its strategic review and the company announced cost-reduction measures. Management has signaled a sharper focus on maximizing value from YUPELRI and preserving financial flexibility. ([investor.theravance.com](https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-inc-reports-fourth-quarter-and-full-year-8?utm_source=openai))
For investors, Theravance Biopharma remains a specialized healthcare name on the NASDAQ in the United States, combining a commercial respiratory asset with residual pipeline and strategic-review optionality. The stock’s profile reflects both biotech execution risk and the potential for value realization through disciplined capital allocation and corporate actions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
